EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: first human trial of TT125-802 begins
Disease control OngoingThis early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors (like lung cancer) that no longer respond to standard therapies. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for any tumor…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Promising new pill aims to keep early lung cancer from coming back
Disease control OngoingThis study tests whether adding the targeted drug zipalertinib to standard chemotherapy after lung cancer surgery can help prevent the cancer from returning. It includes about 360 adults with early-stage (IB-IIIA) non-small cell lung cancer that has uncommon EGFR mutations. Parti…
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
Can a smartphone app and fitbit improve lung cancer care?
Knowledge-focused OngoingThis study involves 30 adults with lung cancer who are taking oral targeted therapy. Participants use a smartphone app, a Fitbit, and a smart pill cap to track symptoms and medication use for up to 24 weeks. The goal is to see if this remote monitoring system is practical and can…
Matched conditions: EGFR
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Lung cancer clue: DNA repair flaw may guide future treatments
Knowledge-focused OngoingThis study looks at a DNA repair issue called homologous recombination deficiency (HRD) in people with a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers want to find out how common HRD is and whether it affects how the cancer behaves or responds to treatmen…
Matched conditions: EGFR
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC